Protein Kinase Inhibitors: all 15,147 studies that test it

Page 124 of 152. Open to participants first (2,533), then studies with results posted, then the rest; newest registration first within each.

• A Study of Sunitinib Versus Placebo in Combination With Lanreotide in Patients With Progressive Advanced/Metastatic Midgut Carcinoid TumorsStatus unknownNCT01731925Phase 2
• Sequential Therapy in Metastatic Renal Cell CarinomaCompletedNCT01731158Phase 2
• Lapatinib+Vinorelbine vs Vinorelbine HER2 Positive Metastatic Breast Cancer Progressed After Lapatinib/TrastuzumabStatus unknownNCT01730677Phase 2
• A Study to Find the Maximum Tolerated Dose of the Experimental Combination of the Drugs INC424 and BKM120 in Patients With Primary or Secondary MyelofibrosisTerminatedNCT01730248Phase 1
• Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis ComplexStatus unknownNCT01730209Phase 2/3
• Gemcitabine Plus Erlotinib in RASH-positive Patients With Metastatic Pancreatic CancerStatus unknownNCT01729481Phase 2
• Afatinib as Cancer Therapy for Exocrine Pancreatic TumoursStatus unknownNCT01728818Phase 2
• Open Label Study of BAY1082439 in Patients With Advanced CancerCompletedNCT01728311Phase 1
• Dacomitinib (PF-00299804) in Advanced/Metastatic Squamous Cell Carcinoma of the PenisCompletedNCT01728233Phase 2
• A Phase I/II Study of Tivozanib and Erlotinib as Initial Treatment for Metastatic Non-small Cell Lung Cancer Assigned by VeriStrat® Serum Proteomic EvaluationWithdrawnNCT01728181Phase 1/2
• Study of REGN1400 Alone and in Combination With Erlotinib or Cetuximab in Patients With Certain Types of CancerCompletedNCT01727869Phase 1
• Pharmacokinetic Study of BKM120 in Subjects With Hepatic ImpairmentCompletedNCT01727128Phase 1
• A Study to Assess the Effect of Food on the Bioavailability of the IGF-1R Inhibitor AXL1717 in Patients With Advanced Malignant TumorsCompletedNCT01725555Phase 1
• Assess the Pharmacokinetics of Rosuvastatin and Simvastatin When Administered Alone or in Combination With FostamatinibCompletedNCT01725230Phase 1
• Tivantinib in Treating Younger Patients With Relapsed or Refractory Solid TumorsCompletedNCT01725191Phase 1
• A Proof of Mechanism Study With GSK2126458 in Patients With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT01725139Phase 1
• A Study to Determine the Relative Bioavailability of the MEK Inhibitor, Trametinib, in Subjects With Solid Tumor MalignanciesCompletedNCT01725100Phase 1
• Study of Frontline Dasatinib Plus Chemotherapy in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (PH+ALL)CompletedNCT01724879Phase 2
• Icotinib or Whole Brain Irradiation in EGFR-mutant Lung CancerCompletedNCT01724801Phase 3
• Whole Brain Radiotherapy (WBRT) With Sorafenib for Breast Cancer Brain Metastases (BCBM)CompletedNCT01724606Phase 1
• PI3K Inhibitor BKM120, Carboplatin, and Pemetrexed Disodium in Treating Patients With Stage IV Non-Small Cell Lung CancerCompletedNCT01723800Phase 1
• Study of LY2157299 in Japanese Participants With CancerCompletedNCT01722825Phase 1
• A Phase I Multiple Ascending Dose Study of ASLAN002 in Subjects With Advanced or Metastatic Solid TumoursCompletedNCT01721148Phase 1
• Increased Dose of Icotinib in Advanced None Small Cell Lung Cancer Patients After Routine Gefitinib TherapySuspendedNCT01720901Phase 4
• Dovitinib for Gastric Cancer With FGFR2 Amplification: GASDOVI-1CompletedNCT01719549Phase 2
• Icotinib Versus First-line Chemotherapy Plus Maintenance Treatment in EGFR Positive Lung Adenocarcinoma PatientsCompletedNCT01719536Phase 3
• Docetaxel, Gemcitabine and Pazopanib as Treatment for Soft Tissue SarcomaCompletedNCT01719302Phase 1/2
• Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin LymphomaCompletedNCT01719250Early Phase 1
• NOV120101 Phase 2 Study in NSCLC Patients With Aquired Resistance to 1st Generation EGFR Tyrosine Kinase InhibitorsCompletedNCT01718847Phase 2
• A Study of Sunitinib in Patients With Advanced CholangiocarcinomaCompletedNCT01718327Phase 2
• Trial of Panitumumab Cisplatin, Fluourouracil and Docetaxel in Locally Advanced or Metastatic Gastric CancerTerminatedNCT01716546Phase 1/2
• Pazopanib Plus Cetuximab for Incurable Head and Neck Squamous Cell Carcinoma (HNSCC)CompletedNCT01716416Phase 1
• Biomarkers Before and After Nephrectomy of Locally Advanced or Metastatic Renal Cell Carcinoma Treated With EverolimusCompletedNCT01715935Phase 2
• Dose Escalation Study Investigating Everolimus and Dovitinib in Metastatic Clear Cell Renal CancerCompletedNCT01714765Phase 1
• Dabrafenib and Pazopanib Hydrochloride in Treating Patients With Advanced Malignant TumorsCompletedNCT01713972Phase 1
• Pazopanib in Relapsed and Refractory Small Cell Lung CancerCompletedNCT01713296Phase 2
• A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With CrizotinibCompletedNCT01712217Phase 1/2
• A Study to Evaluate the Long-term Safety and Efficacy of ASP015K in Subjects Previously Enrolled in a Phase 2 ASP015K Rheumatoid Arthritis StudyCompletedNCT01711814Phase 2
• A Pharmacokinetics Study of Radioactive-Labeled GDC-0973 in Healthy Male VolunteersCompletedNCT01711762Phase 1
• Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple MyelomaCompletedNCT01711528Phase 1
• Letrozole and CDK 4/6 Inhibitor for ER Positive, HER2 Negative Breast Cancer in Postmenopausal WomenStatus unknownNCT01709370Phase 2
• Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid CancerActive, not recruitingNCT01709292Phase 2
• The Impact of Everolimus Based Immunosuppression in the Evolution of Hepatitis C Fibrosis After Liver TransplantationCompletedNCT01707849Phase 3
• Icotinib in Combination With Chemotherapy Versus Chemotherapy Alone in Patients Progressed After Icotinib TreatmentStatus unknownNCT01707329Phase 2
• Safety and Efficacy of the Early Introduction of Everolimus (Certican®) With Low Dose of Cyclosporine in de Novo Kidney Recipients After 1 Month of TransplantationCompletedNCT01706471Phase 4
• A Phase 1b Study Evaluating GS-9820 in Subjects With Lymphoid MalignanciesCompletedNCT01705847Phase 1
• Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By SurgeryTerminatedNCT01705340Phase 1
• A Study to Evaluate the Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Patients With Recurrent Mature B-Cell NeoplasmsCompletedNCT01704963Phase 1
• A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Adult Participants With Advanced or Refractory Solid Tumors or LymphomaCompletedNCT01703481Phase 1
• Activity of Sorafenib in Salivary Gland CancerCompletedNCT01703455Phase 2
• Evaluation Of The Potential Effect That The Administration Of Food Or Antacid Medication May Have In The Oral Absorption Of Dacomitinib (PF-00299804)CompletedNCT01702506Phase 1
• Phase I Study to Assess the Safety, Tolerability, and Pharmacokinetics of Orally Administered CUDC-101 in Cancer PatientsTerminatedNCT01702285Phase 1
• Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) PatientsCompletedNCT01702064Phase 1
• Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab to Treat Stage IV Lung CancerCompletedNCT01700400Phase 1
• Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors.CompletedNCT01700270Phase 1
• Trial of Lapatinib and Weekly Paclitaxel for Advanced Urothelial CancerWithdrawnNCT01700010Phase 2
• A Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 in Patients With Elevated Intraocular Pressure for 3 MonthsCompletedNCT01699464Phase 2
• The Biomarker for Immunosuppressive Agents Metabolism in Chinese Renal Transplant RecipientsStatus unknownNCT01699360Phase 4
• Phase 1 Study of TG02 Citrate in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic LymphomaCompletedNCT01699152Phase 1
• Effect of Tivantinib on the QTC Interval in Cancer SubjectsCompletedNCT01699061Phase 1
• A Phase I Study of Oral BGJ398 in Asian PatientsCompletedNCT01697605Phase 1
• Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin LymphomaActive, not recruitingNCT01695941Phase 1
• Masitinib in Patients With Gastrointestinal Stromal Tumour After Progression With ImatinibCompletedNCT01694277Phase 3
• Multiple Dose-escalation Study of AMA0076 in Patients With Ocular Hypertension or Primary Open-angle GlaucomaCompletedNCT01693315Phase 2
• Phase 2 Study in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With SplenomegalyCompletedNCT01692366Phase 2
• Safety and Pharmacokinetics of AVL-292 Following Multiple Doses and the Effect of Food on the Single-dose Pharmacokinetics of AVL-292CompletedNCT01692184Phase 1
• A Phase II Study of Orally Administered BEZ235 Monotherapy in Patients With Metastatic or Unresectable Malignant PEComaWithdrawnNCT01690871Phase 2
• Dose Escalation of Icotinib in Advanced Non-small Cell Lung Carcinoma (NSCLC) Patients Evaluated as Stable DiseaseStatus unknownNCT01690390Phase 2
• Nilotinib-Chemotherapy in CML Myeloid BP or Bcr-abl(+) AMLStatus unknownNCT01690065Phase 2
• Hydroxychloroquine, Cyclophosphamide, Dexamethasone, and Sirolimus in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT01689987Phase 1
• Phase II Trial of Double Dose of Icotinib in Treating Brain Metastases From Non-small Cell Lung CancerStatus unknownNCT01688713Phase 2
• The Effect of Ursodeoxycholic Acid in Liver Functional Restoration of Patients With Obstructive JaundiceStatus unknownNCT01688375Phase 2
• A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of GSK2586184 and the Effect of Food and GenderCompletedNCT01687309Phase 1
• A Phase I Study to Compare 3 Different Strengths of an Extended Release Formulation of ASP015K to an Immediate Release Formulation of ASP015KCompletedNCT01686217Phase 1
• Abiraterone Acetate and Prednisone With or Without Dasatinib in Treating Patients With Metastatic Hormone-Resistant Prostate CancerStatus unknownNCT01685125Phase 2
• Gemcitabine Plus Rapamycin Versus Gemcitabine to Treat Advanced Soft Tissue SarcomaCompletedNCT01684449Phase 1/2
• Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney CancerActive, not recruitingNCT01684397Phase 1/2
• An Dose Escalation Trial of Oral BIBF 1120 in Combination With Intravenous Vinorelbine in Elderly Patients With Advanced Non Small Lung Cell Cancer - Stage IV (VENUS-1)CompletedNCT01684111Phase 1
• An Dose Escalation Trial of Oral BIBF 1120 in Combination With Intravenous Carboplatin and Vinorelbine in Elderly Patients With Advanced Non-Small Cell Lung Cancer - Stage IV (VENUS-2)CompletedNCT01683682Phase 1
• Erlotinib in Post Radical Operation NSCLC Patients With EGFR MutationStatus unknownNCT01683175Phase 2
• Sorafenib and Topotecan in Refractory/Recurrent Pediatric MalignanciesCompletedNCT01683149Phase 1
• A Study of ZSTK474 in Japanese Patients With Advanced Solid MalignanciesCompletedNCT01682473Phase 1
• Dovitinib Combined With Bortezomib and Dexamethasone for Relapsed/Refractory Multiple MyelomaWithdrawnNCT01680796Phase 1
• Sirolimus for Massive Polycystic LiverStatus unknownNCT01680250Phase 2/3
• A Phase II Study of Dovitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary GlandsCompletedNCT01678105Phase 2
• Combining MLN8237 With Nab-Paclitaxel in Patients With Advanced Solid MalignanciesCompletedNCT01677559Phase 1
• A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell CarcinomaTerminatedNCT01677390Phase 1
• Phase 1b Trial of Dinaciclib With Pembrolizumab for Advanced Breast CancerCompletedNCT01676753Phase 1
• Intravitreal Injections of Sirolimus in the Treatment of Geographic AtrophyTerminatedNCT01675947Phase 2
• A Study to Determine the Absorption, Metabolism, and Routes of Excretion of (14C) Radiolabeled Ibrutinib in Healthy Male ParticipantsCompletedNCT01674322Phase 1
• A Phase I/Ib Trial for the Evaluation of SAR260301 in Monotherapy or in Combination With Vemurafenib in Patients With Various Advanced CancerCompletedNCT01673737Phase 1
• Sirolimus With Cyclophosphamide and Topotecan for Pediatric/Adolescent Relapsed and Refractory Solid TumorsCompletedNCT01670175Phase 1
• Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous LeukemiaWithdrawnNCT01670084Phase 2
• Dose-ranging Study With GLPG0634 in Methotrexate-refractory Active Rheumatoid Arthritis PatientsCompletedNCT01668641Phase 2
• A Phase I Study of AZD0424 Alone and in Combination in Advanced Solid TumoursTerminatedNCT01668550Phase 1
• Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver CancerCompletedNCT01666756Phase 1
• NOA-12: BIBF1120 and R-RT in GlioblastomaTerminatedNCT01666600Phase 1/2
• Single-center Investigator Initiated Pilot Study Investigating the Tumor Response of Squamous Cell Carcinoma Lesions in Patients Under Lapatinib TreatmentTerminatedNCT01666431Phase 2
• Pilot Study Investigating the Metabolic Activity and Transcriptional Profiling in Vivo in Tumor Biopsies in Melanoma Patients During Treatment With Pazopanib Alone and in Combination With PaclitaxelCompletedNCT01666418Phase 2
• Single and Multiple Dose Pharmacokinetics of GLPG0634 in Elderly Healthy SubjectsCompletedNCT01665924Phase 1

← Protein Kinase Inhibitors overview